SCHEMBL13435182

SCHEMBL13435182

Cc1cccc(C)c1CC1CCN(C2C3CC4CC(C3)CC2C4)C1=O

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.67
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD11B2 P80365 1/20 0.34
EPHX2 P34913 1/20 0.32
MC4R P32245 1/20 0.31
USP2 O75604 1/20 0.31
ROCK2 O75116 1/20 0.31
C5AR1 P21730 1/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
GAA P10253 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
XIAP P98170 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13435175 0.93 HSD11B1 (0.57) HSD11B1ALDH1A1SMN1; SMN2HSD11B2EPHX2
SCHEMBL13435165 0.88 HSD11B1 (0.61) HSD11B1ALDH1A1SMN1; SMN2HSD11B2EPHX2
SCHEMBL14186616 0.84 HSD11B1 (0.48) HSD11B1
SCHEMBL3427426 0.82 HSD11B1 (0.78) HSD11B1ALDH1A1SMN1; SMN2USP2MEN1
SCHEMBL3426077 0.81 HSD11B1 (0.53) HSD11B1ALDH1A1SMN1; SMN2HSD11B2EPHX2
SCHEMBL13435191 0.80 HSD11B1 (1.00) HSD11B1ALDH1A1USP2ROCK2KMT2A
SCHEMBL13435181 0.78 HSD11B1 (0.68) HSD11B1ALDH1A1GAAKMT2A
SCHEMBL13435186 0.78 HSD11B1 (0.76) HSD11B1EPHX2ROCK2
SCHEMBL3421958 0.77 HSD11B1 (0.70) HSD11B1ALDH1A1SMN1; SMN2ROCK2GAA
SCHEMBL13435170 0.77 HSD11B1 (0.73) HSD11B1ALDH1A1SMN1; SMN2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687644-B2 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-03-30 US disclosed
US-7687644-B2 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-03-30 US disclosed
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 US disclosed
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors HSD11B1, HSD11B2, HSDL2 HSD11B1 1/4885ALDH1A1 99/4885SMN1; SMN2 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.